CCCC

CCCC

USD

C4 Therapeutics Inc. Common Stock

$2.325-0.025 (-1.064%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$2.350

High

$2.420

Low

$2.290

Volume

1.58M

Company Fundamentals

Market Cap

225.3M

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

1.92M

Exchange

NMS

Currency

USD

52-Week Range

Low $1.085Current $2.325High $6.2

Related News

Analyst Upgrades

Wells Fargo Maintains Overweight on C4 Therapeutics, Raises Price Target to $10

Wells Fargo analyst Derek Archila maintains C4 Therapeutics with a Overweight and raises the price target from $5 to $10.

View more
Wells Fargo Maintains Overweight on C4 Therapeutics, Raises Price Target to $10
Analyst Upgrades

Stephens & Co. Reiterates Overweight on C4 Therapeutics, Maintains $6 Price Target

Stephens & Co. analyst Sudan Loganathan reiterates C4 Therapeutics with a Overweight and maintains $6 price target.

View more
Stephens & Co. Reiterates Overweight on C4 Therapeutics, Maintains $6 Price Target
GlobeNewswire

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple

View more
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
Analyst Upgrades

Barclays Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $8

Barclays analyst Etzer Darout initiates coverage on C4 Therapeutics with a Overweight rating and announces Price Target of $8.

View more
Barclays Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $8
Analyst Upgrades

Stephens & Co. Upgrades C4 Therapeutics to Overweight, Raises Price Target to $6

Stephens & Co. analyst Sudan Loganathan upgrades C4 Therapeutics from Equal-Weight to Overweight and raises the price target from $3 to $6.

View more
Stephens & Co. Upgrades C4 Therapeutics to Overweight, Raises Price Target to $6
PR Newswire

Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market

USA News Group News Commentary – The FDA's unprecedented wave of Breakthrough Therapy Designations through August has accelerated development...

GlobeNewswire

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced